{
    "organizations": [],
    "uuid": "620969bd91b988f8ad4fb209373d9485d7f3df13",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/03/globe-newswire-fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2018-financial-results.html",
    "ord_in_thread": 0,
    "title": "Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SAN DIEGO, Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, May 10, 2018 at 5:00 p.m. ET to report its first quarter 2018 financial results and provide a corporate update.\nIn order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 5592629. The live webcast can be accessed under \"Events & Presentations\" in the Investors and Media section of the Company's website at www.fatetherapeutics.com . The archived webcast will be available on the Company's website beginning approximately two hours after the event.\nAbout Fate Therapeutics, Inc.\nFate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Fate Therapeutics is headquartered in San Diego, CA.\nContact:\nChristina Tartaglia\nStern Investor Relations, Inc.\n212.362.1200\nchristina@sternir.com\nSource:Fate Therapeutics, Inc.",
    "published": "2018-05-04T00:01:00.000+03:00",
    "crawled": "2018-05-04T02:49:21.015+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "san",
        "diego",
        "fate",
        "therapeutic",
        "nasdaq",
        "fate",
        "biopharmaceutical",
        "company",
        "dedicated",
        "development",
        "programmed",
        "cellular",
        "immunotherapy",
        "cancer",
        "immune",
        "disorder",
        "announced",
        "today",
        "company",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "thursday",
        "may",
        "et",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "order",
        "participate",
        "conference",
        "call",
        "please",
        "dial",
        "domestic",
        "international",
        "refer",
        "conference",
        "id",
        "live",
        "webcast",
        "accessed",
        "event",
        "presentation",
        "investor",
        "medium",
        "section",
        "company",
        "website",
        "archived",
        "webcast",
        "available",
        "company",
        "website",
        "beginning",
        "approximately",
        "two",
        "hour",
        "event",
        "fate",
        "therapeutic",
        "fate",
        "therapeutic",
        "biopharmaceutical",
        "company",
        "engaged",
        "development",
        "programmed",
        "cellular",
        "immunotherapy",
        "cancer",
        "immune",
        "disorder",
        "company",
        "hematopoietic",
        "cell",
        "therapy",
        "pipeline",
        "comprised",
        "program",
        "including",
        "product",
        "candidate",
        "derived",
        "engineered",
        "induced",
        "pluripotent",
        "cell",
        "line",
        "program",
        "including",
        "product",
        "candidate",
        "prevent",
        "complication",
        "patient",
        "undergoing",
        "hematopoietic",
        "cell",
        "transplantation",
        "promote",
        "immune",
        "tolerance",
        "patient",
        "autoimmune",
        "disease",
        "fate",
        "therapeutic",
        "headquartered",
        "san",
        "diego",
        "ca",
        "contact",
        "christina",
        "tartaglia",
        "stern",
        "investor",
        "relation",
        "christina",
        "source",
        "fate",
        "therapeutic",
        "inc"
    ]
}